TRPM2 and breast adenocarcinoma: Recent data from Hopkins MM et al. demonstrated that TRPM2 was present in the nuclei of MCF-7 and MDA-MB-231 human breast adenocarcinoma cells, and its pharmacologic inhibition or RNAi silencing caused the decreased cell proliferation and the 4-fold increases in DNA damage levels, suggesting a novel effect of TRPM2, where it functions to minimize DNA damage and thus may have a role in the protection of genomic DNA in breast cancer cells48.